Named Patient Program vs Compassionate Use Program in India: A Complete Guide for Patients and Physicians

Home >> Article >> Named Patient Program vs Compassionate Use Program in India: A Complete Guide for Patients and Physicians

Named Patient Program vs Compassionate Use Program in India: A Complete Guide for Patients and Physicians

In India, access to life-saving treatments can sometimes feel like a race against time—especially when a medicine is approved globally but not yet available locally. For patients with serious or rare diseases, Named Patient Programs (NPP) and Compassionate Use Programs (CUP) offer critical pathways to access such unapproved or unavailable treatments.

But how do these programs work in India? And what are the key differences?

This guide explains everything you need to know about Named Patient Programs vs Compassionate Use Programs in India, including regulatory pathways, eligibility, and how to access treatment.

Understanding Early Access to Medicines in India:

India regulates access to unapproved or unavailable medicines through the Central Drugs Standard Control Organization (CDSCO) under the Drugs and Cosmetics Act, 1940.

Unlike the US or Europe, India does not always use standardized terms like “Named Patient Program.” However, similar access is granted through:

Import of unapproved drugs
Physician-led requests for individual patients
Special regulatory approvals

These pathways are important for patients who cannot wait for full drug approval in India.

What is a Named Patient Program (NPP) in India?

A Named Patient Program in India refers to a regulatory pathway that allows a patients and physician to request access to a medicine that is:

Approved in another country but not in India
Not commercially available locally
Medically necessary for a specific patient

How It Works in India?

Access is typically granted through:

Form 12B under CDSCO regulations
Import of small quantities of unapproved drugs
Prescription and justification by a licensed physician

Key Features:

Patient-specific access
Requires strong medical justification
Often used for oncology, rare diseases, and critical care
Faster than waiting for full drug approval in India

What is a Compassionate Use Program (CUP) in India?

A Compassionate Use Program in India provides access to investigational drugs that are:

Still under clinical development
Not approved in any country yet
Showing promising results in trials

How It Works in India?

Compassionate use is more limited and may involve:

Special permissions from CDSCO
Clinical trial extensions or expanded access
Direct involvement of pharmaceutical companies

Key Features

Can include individual or group access
Requires strict regulatory and ethical approvals
Typically used for life-threatening conditions
Often complex and time-sensitive

Named Patient Program vs Compassionate Use Program in India:

Named Patient Program vs Compassionate Use Program has some below listed key differences:

Feature	Named Patient Program (NPP)	Compassionate Use Program (CUP)
Drug Status	Approved in another country	Not yet approved anywhere
Regulatory Route	CDSCO Form 12B import	Special CDSCO approvals
Access Type	Individual patient request	Individual or group access
Initiator	Physician	Pharma company + physician
Regulatory Complexity	Moderate	High
Use Case	Access to approved but unavailable drugs	Access to investigational treatments

When Should Patients in India Consider These Programs?

Named Patient Program is suitable when:

The drug is approved in the US, EU, or other markets
It is not yet available in India
Immediate treatment is required
A physician can justify its use

Compassionate Use is suitable when:

No approved treatment exists globally
The patient cannot join a clinical trial
The drug is still experimental but promising

Challenges in Accessing Medicines in India:

Patients in India often face unique barriers:

Delayed drug approvals compared to global markets
Complex regulatory procedures
Limited awareness of access pathways
High costs of imported medicines

This makes expert guidance and coordination essential for successful access.

How Ikris Pharma Network Supports Patients and Physicians?

In moments when time is important and options feel limited, the journey to treatment should feel guided—not overwhelming.

Ikris Pharma Network helps simplify the NPP journey by providing:

Clear, up-to-date information on Named Patient Program pathways in India
Support in connecting physicians and global pharmaceutical manufacturers
Guidance through CDSCO application and approval processes
Advocacy focused on equitable access to treatment worldwide

Behind every request is a human story—and Ikris works to ensure that story continues with hope.

Expanding Access to Life-Saving Treatments:

For patients with serious or life-threatening disease/conditions in India, waiting is not always an option. Named Patient Programs create a bridge—bringing globally approved treatments closer to those who need them now. Compassionate Use Programs open a window to the future—offering access to therapies still in development.

Together, they represent more than regulatory pathways—they represent possibility, access, and a second chance when it matters most.

If you or someone you care for is exploring access to unapproved medicines in India, Ikris Pharma Network is here to guide you through every step—helping you navigate options, processes, and possibilities with clarity and confidence.

Frequently Asked Questions (FAQs):

What is the difference between Named Patient Program vs Compassionate Use in India?

The Named Patient Programs in India allow access to drugs approved abroad (but not in India), while Compassionate Use provides investigational treatments. Both require CDSCO approvals but differ in drug status and regulatory complexity.

Is Named Patient Program legal in India?

Yes, Named Patient Programs are legal in India under CDSCO regulations. Patients can access unapproved drugs when prescribed by a physician for life-threatening medical conditions.

How do Named Patient Program companies support patients in India?

Companies like Ikris Pharma Network support patients and physicians by preparing form 12A/12B documentation, liaising with CDSCO/customs, ensuring compliant, temperature-controlled shipping, and tracking regulatory updates and approval timelines.

This makes the pathway smoother for families already burdened with high disease-related stress.

Who can help in importing a medicine not available in India?

Ikris Pharma Network assist patients and physicians in importing medicines not available in India. The company is known for managing regulatory approvals, sourcing drugs globally, and ensuring compliant Named Patient Program access.

Who is the leading Named Patient Program company in India?

Ikris Pharma Network is recognized as a leading Named Patient Program company in India. We offer global access solutions, regulatory expertise, and patient-focused support for obtaining unapproved or hard-to-access medicines.

Disclaimer:

Ikris Pharma Network sources prescribed medicines directly from manufacturers or authorized distributors. We do not own or claim any trademarks related to these medicines. All trademarks belong to their respective owners.

We follow the guidelines of the Trademark Act, 1999, including fair use provisions. Our role is only to help patients access newly launched medicines through named patient import.

24-03-2026

Written By:

Nitin